Set for a major rebound on major new catalysts
Bullish pennant formed just prior to FDA putting a partial hold on Inovio's Covid-19 vaccine P2/P3 trials.
Inovio is expected to resolve the FDA's questions within the next 30 days and begin trials with "EXTENSIVE external funding" according to CEO - Dr. Joseph Kim
Inovio is expected to resolve the FDA's questions within the next 30 days and begin trials with "EXTENSIVE external funding" according to CEO - Dr. Joseph Kim
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.